These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15675599)

  • 21. Medical journal criticizes Merck over Vioxx data.
    Berenson A
    N Y Times Web; 2005 Dec; ():A1, C13. PubMed ID: 16456990
    [No Abstract]   [Full Text] [Related]  

  • 22. Avoiding another Vioxx.
    Beardsley S
    Sci Am; 2005 Feb; 292(2):16, 18. PubMed ID: 15715381
    [No Abstract]   [Full Text] [Related]  

  • 23. Merck's actions surrounding Vioxx.
    Heinley M
    PLoS Med; 2006 Jun; 3(6):e286; author reply e285. PubMed ID: 16789808
    [No Abstract]   [Full Text] [Related]  

  • 24. [The case of rofecoxib(Vioxx)-what do we learn from this case].
    Vuorenkoski L
    Duodecim; 2006; 122(4):385-6. PubMed ID: 16623094
    [No Abstract]   [Full Text] [Related]  

  • 25. Causation, Vioxx, and legal issues.
    Green MD
    Science; 2005 Nov; 310(5750):973. PubMed ID: 16284163
    [No Abstract]   [Full Text] [Related]  

  • 26. What happened to the coxibs on the way to the cardiologist?
    Alberts DS; Potter JD; Martinez ME; Hess LM; Stopeck A; Lance P
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):555-6. PubMed ID: 15767326
    [No Abstract]   [Full Text] [Related]  

  • 27. Quebec allows Vioxx class-action suit.
    Sibbald B
    CMAJ; 2007 Jan; 176(1):20. PubMed ID: 17200378
    [No Abstract]   [Full Text] [Related]  

  • 28. Was Vioxx really that dangerous?
    Park A
    Time; 2005 Feb; 165(9):52. PubMed ID: 15765852
    [No Abstract]   [Full Text] [Related]  

  • 29. Merck accused of disguising its role in research.
    Cressey D
    Nature; 2008 Apr; 452(7189):791. PubMed ID: 18431823
    [No Abstract]   [Full Text] [Related]  

  • 30. Vioxx award good news for Canadian lawsuits.
    Eggertson L
    CMAJ; 2005 Sep; 173(7):744. PubMed ID: 16186576
    [No Abstract]   [Full Text] [Related]  

  • 31. The law. Vioxx verdict: too little or too much science?
    Lawler A
    Science; 2005 Sep; 309(5740):1481. PubMed ID: 16141043
    [No Abstract]   [Full Text] [Related]  

  • 32. Make or break time in Vioxx drama.
    Nature; 2006 Mar; 440(7082):277. PubMed ID: 16541045
    [No Abstract]   [Full Text] [Related]  

  • 33. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
    Willis KD
    Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
    [No Abstract]   [Full Text] [Related]  

  • 34. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 35. Perspectives on drug withdrawals.
    Williams R
    CMAJ; 2005 Jul; 173(2):129. PubMed ID: 16027417
    [No Abstract]   [Full Text] [Related]  

  • 36. Open conflict on the handling of the Merck drug Vioxx by editorial giants.
    Edwards RG
    Reprod Biomed Online; 2006 Dec; 13(6):905. PubMed ID: 17169217
    [No Abstract]   [Full Text] [Related]  

  • 37. Bringing Vioxx back to market.
    Ross JS; Krumholz HM
    BMJ; 2018 Jan; 360():k242. PubMed ID: 29371221
    [No Abstract]   [Full Text] [Related]  

  • 38. Manipulating a journal article.
    N Y Times Web; 2005 Dec; ():WK11. PubMed ID: 16453395
    [No Abstract]   [Full Text] [Related]  

  • 39. Vioxx and Merck: a preventable situation?
    Torg J
    Orthopedics; 2005 Mar; 28(3):248, 250. PubMed ID: 15790082
    [No Abstract]   [Full Text] [Related]  

  • 40. Vioxx doctors wooed by Merck are now its foes.
    Tesoriero HW
    Wall St J (East Ed); 2006 Mar; ():B1, B3. PubMed ID: 16578911
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.